Latham & Watkins Advises Ascendis Pharma on Nasdaq Ordinary Share Listing

Ascendis Pharma A/S (Nasdaq: ASND), a global biopharmaceutical company focused on applying its TransCon technology platform to develop therapies addressing unmet medical needs, has announced the commencement of trading of its ordinary shares on the Nasdaq Global Select Market. In connection with the listing, Ascendis Pharma has exchanged all outstanding American Depositary Shares (ADSs) for ordinary shares. The ordinary shares trade under the same ticker symbol ASND as previously used for the ADS listing. 

Latham & Watkins LLP represented Ascendis Pharma in the transaction with a corporate team led by Bay Area partners John Williams and Mark Roeder, with associates Paul Lau, Keran Huang, and Taleah Tyrell. Advice was also provided on tax matters by New York partner Elena Romanova, with assistance from Ethan Lee; on compensation and benefits matters by Bay Area partner Maj Vaseghi; and on convertible notes matters by New York partner Ryan Gold.